• Publications
  • Influence
Predictors of hospital mortality in the global registry of acute coronary events.
TLDR
Across the entire spectrum of ACS and in general clinical practice, this model provides excellent ability to assess the risk for death and can be used as a simple nomogram to estimate risk in individual patients. Expand
Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE)
TLDR
This risk prediction tool uses readily identifiable variables to provide robust prediction of the cumulative six month risk of death or myocardial infarction and can guide patient triage and management across the spectrum of patients with acute coronary syndrome. Expand
A validated prediction model for all forms of acute coronary syndrome:estimating the risk of 6-month postdischarge death in an international registry
TLDR
The GRACE 6-month postdischarge prediction model is a simple, robust tool for predicting mortality in patients with ACS and Clinicians may find it simple to use and applicable to clinical practice. Expand
Apixaban with antiplatelet therapy after acute coronary syndrome.
TLDR
The addition of apixaban, at a dose of 5 mg twice daily, to antiplatelet therapy in high-risk patients after an acute coronary syndrome increased the number of major bleeding events without a significant reduction in recurrent ischemic events. Expand
Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006.
TLDR
Improvements in the management of patients with ACS were associated with significant reductions in the rates of new heart failure and mortality and in rates of stroke and mycoardial infarction at 6 months. Expand
Platelet inhibition with cangrelor in patients undergoing PCI.
TLDR
Cangrelor was not superior to an oral loading dose of 600 mg of clopidogrel, administered 30 minutes before PCI, in reducing the composite end point of death from any cause, myocardial infarction, or ischemia-driven revascularization at 48 hours. Expand
Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE).
TLDR
The GRACE study reveals substantial differences in the management of patients based on hospital type and geographical location and will determine whether such variations translate into differences in longer term outcomes. Expand
Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY
TLDR
Enoxaparin was not superior to unfractionated heparin but was noninferior for the treatment of high-risk patients with non-ST-segment elevation ACS and the advantages of convenience should be balanced with the modest excess of major bleeding. Expand
Intravenous platelet blockade with cangrelor during PCI.
TLDR
The use of periprocedural cangrelor during PCI was not superior to placebo in reducing the primary end point, and the prespecified secondary end points of stent thrombosis and death were lower in the cang Relor group, with no significant increase in the rate of transfusion. Expand
Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation
TLDR
In patients with atrial fibrillation and a recent acute coronary syndrome or PCI treated with a P2Y12 inhibitor, an antithrombotic regimen that included apixaban, without aspirin, resulted in less bleeding and fewer hospitalizations without significant differences in the incidence of ischemic events than regimens that included a vitamin K antagonist, aspirin, or both. Expand
...
1
2
3
4
5
...